Global Antiretroviral Protease Inhibitor Market Top Leading Players with Strategies and Forecast 2022-2028

The global antiretroviral protease inhibitor market is anticipated to grow at a significant CAGR 5% during the forecast period (2022-2028). Proteolysis is the process of breaking down proteins into smaller polypeptides or single amino acids, and a protease is an enzyme molecule that catalyzes this process. A protease inhibitor is a chemical that prevents a protease from working. Antiretroviral protease inhibitors are antiretroviral medications that are used to treat diseases such as HIV. They stop HIV from multiplying by inhibiting the activity of the enzyme HIV protease. Protease inhibitors are being used in a variety of fields. They’re utilized as medications to treat diseases such as HIV/AIDS and Hepatitis C, among others.

Antiretroviral protease inhibitors are widely used to treat diseases including HIV and HCV. According to the UNAIDS, 37.7 million people across the globe are suffering from the HIV in 2020 and according to the WHO, 58 million people across the globe are suffering from HCV in 2019. Thus, with the rising prevalence of these diseases, the demand for antiretroviral protease inhibitors will further grow during the forecast period.

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, in order to stay competitive in the market. For instance-

• In July 2021, Unitaid and CHAI announced a pricing agreement with Hetero Labs LTD, that will boost darunavir with ritonavir (DRV/r) available as second-line therapy for persons living with HIV in low- and middle-income countries for $210 per patient, per year. Darunavir (DRV) in combination with ritonavir is a best-in-class protease inhibitor that has been found to be successful in the treatment of individuals with HIV and has developed multi-drug resistance. DRV is less toxic and easier to take than other protease inhibitors currently used in second-line treatment.
• In June 2021, The USFDA approved Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200 mg/300 mg of Lupin. Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200 mg/300 mg are the generic equivalents of Gilead Sciences, Inc’s Truvada Tablets 200 mg/300 mg, and are used to treat HIV-1 infection in combination with other antiretroviral drugs.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Mechanism of Action
  • By Disease Indication
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

· Competitive Landscape- Janssen Pharmaceuticals Company Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Merck & Co., Inc., AbbVie Inc., and Bristol Myers Squibb, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Antiretroviral Protease Inhibitor Market Report by Segment

By Mechanism of Action

• Serine Protease Inhibitors
• Cysteine Protease Inhibitors
• Amino Peptidase Inhibitor
• Aspartic Protease Inhibitors
• Metallo-Protease Inhibitors
• Others

By Disease Indication

• HIV/AIDS
• Hepatitis C
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Antiretroviral Protease Inhibitor Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa